Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $82.5M | $85.5M | $87.2M | $107M | $108M | $98.3M | $132M | $159M | $164M | $191M |
| Revenue growth | — | 3.7% | 1.9% | 22.5% | 0.9% | -8.8% | 34.2% | 20.3% | 3.7% | 16.2% |
| Gross profit | $25.1M | $26.2M | $25.6M | $31.2M | $29.2M | $24.6M | $29.4M | $39.2M | $42.3M | $46.0M |
| Gross margin | 30.4% | 30.7% | 29.3% | 29.2% | 27.1% | 25.1% | 22.3% | 24.7% | 25.7% | 24.1% |
| Operating income | $3.76M | $6.48M | $6.55M | $7.37M | $5.70M | $35.0K | $129K | $9.47M | $9.96M | -$5.90M |
| Operating margin | 4.6% | 7.6% | 7.5% | 6.9% | 5.3% | 0.0% | 0.1% | 6.0% | 6.1% | -3.1% |
| Net income | $3.51M | $7.65M | $24.9M | $5.21M | $5.23M | -$234K | -$119K | $7.20M | $6.31M | -$5.90M |
| Net margin | 4.3% | 8.9% | 28.6% | 4.9% | 4.9% | -0.2% | -0.1% | 4.5% | 3.8% | -3.1% |
| EPS (diluted) | $0.23 | $0.48 | $1.53 | $32.00 | $0.33 | $0.05 | $0.05 | $0.44 | $38.00 | -$35.00 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $7.65M | $7.27M | $10.9M | -$2.97M | $21.7M | $4.33M | -$1.26M | $1.93M | $16.6M | $11.0M |
| Capital expenditures | $1.22M | $1.39M | $4.18M | $6.28M | $3.10M | $2.81M | $1.68M | $2.55M | $1.93M | $3.87M |
| Free cash flow | $6.43M | $5.88M | $6.70M | -$9.25M | $18.6M | $1.51M | -$2.94M | -$623K | $14.7M | $7.12M |
| Share buybacks | $607K | — | $742K | $1.96M | $0.00 | — | — | — | — | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $10.7M | $18.2M | $25.6M | $7.13M | $10.6M | $8.33M | $5.63M | $10.2M | $6.85M | $9.35M |
| Total assets | $84.7M | $97.2M | $121M | $145M | $138M | $160M | $168M | $178M | $220M | $217M |
| Total liabilities | $16.9M | $18.1M | $16.4M | $34.8M | $20.8M | $41.8M | $52.0M | $52.8M | $86.3M | $86.8M |
| Long-term debt | — | — | — | $15.8M | $0.00 | $18.9M | $19.3M | $23.6M | $51.5M | $45.5M |
| Shareholders' equity | $68.0M | $79.2M | $105M | $110M | $117M | $118M | $116M | $125M | $134M | $130M |
| Retained earnings | -$90.5M | -$82.9M | -$58.0M | -$52.8M | -$47.6M | -$47.8M | -$48.0M | -$40.8M | -$34.4M | -$40.3M |
| Shares (wtd avg diluted) | 15.4M | 15.9B | 16.3M | 16.2M | 16.1B | 16.0M | 16.1M | 16.2M | 16.8M | 16.6M |
Every figure is extracted from ULTRALIFE CORP’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.